Solid Biosciences

138 articles about Solid Biosciences

• Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2024

  4/3/2024

  Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced the grant of inducement awards to two newly hired employees.

• Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

  4/1/2024

  Solid Biosciences Inc. (Nasdaq: SLDB) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.

• Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium

  3/27/2024

  Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks, M.D., Chief Medical Officer, will present at Cantor’s Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 8:15 am ET.

• Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

  3/13/2024

  Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

• Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD

  3/7/2024

  Solid Biosciences Inc. and collaboration agreement with Armatus Bio for the use of Solid’s proprietary capsid AAV-SLB101 for the development and commercialization of Armatus’ vectorized RNAi candidate to treat Facioscapulohumeral muscular dystrophy (FSHD).

• Solid Biosciences to Participate at Upcoming Investor Conferences - March 6, 2024

  3/6/2024

  Solid Biosciences Inc. today announced participation in the following investor conferences.

• Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

  1/16/2024

  Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.

• Solid Biosciences Announces $109 Million Private Placement

  1/8/2024

  Solid Biosciences Inc. announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement, which is expected to close on or about January 11, 2024, subject to the satisfaction of customary closing conditions.

• Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference

  1/4/2024

  Solid Biosciences Inc. today announced that Bo Cumbo, President and Chief Executive Officer, will present at the J.P Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:45 am PT.

• Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003

  12/7/2023

  Solid Biosciences Inc. today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003.

• Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

  11/22/2023

  Solid Biosciences Inc. today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Thursday, November 30, 2023, at 1:00 pm ET.

• Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

  11/14/2023

  Solid Biosciences Inc. (Nasdaq: SLDB) today announced that it has received U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SGT-003, the company’s next-generation Duchenne Muscular Dystrophy (Duchenne) gene therapy candidate.

• Solid Biosciences to Participate at Jefferies London Healthcare Conference

  11/9/2023

  Solid Biosciences Inc. today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023, at 5:00 pm GMT.

• Solid Biosciences Provides Third Quarter Business Update and Financial Results

  11/8/2023

  Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

• Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

  10/2/2023

  Solid Biosciences Inc. today announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer.

• Solid Biosciences to Participate at Upcoming Investor Conferences - September 20, 2023

  9/20/2023

  Solid Biosciences Inc. today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following three upcoming investor conferences.

• Solid Biosciences to Participate at Upcoming Investor Conferences

  9/5/2023

  Solid Biosciences Inc. today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following two upcoming investor conferences.

• Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference

  8/31/2023

  Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Citi 18th Annual BioPharma Conference on Thursday, September 7, 2023, at 9:40 AM ET.

• Solid Biosciences Provides Second Quarter Business Update and Financial Results

  8/14/2023

  Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a business update.

• Solid Biosciences to Participate at the 2023 Jefferies Healthcare Conference

  6/1/2023

  Solid Biosciences Inc. announced that Bo Cumbo, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 3:00 PM ET.